An inexpensive point-of-care immunochromatographic test for *Talaromyces marneffei* infection based on the yeast phase specific monoclonal antibody 4D1 and *Galanthus nivalis* agglutinin

Kritsada Pruksaphon1, Akarin Intaramat2, Pavinee Simsiriwong2, Skorn Mongkolsuk2, Kavi Ratana Banangkoong3, Joshua D. Nosanchuk4, Anna Kaltsas5,6, Sirida Youngchim7

1 Graduate Program in Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, 2 Translational Research Unit, Laboratory of Immunology and Laboratory of Biotechnology, Chulabhorn Research Institute, Bangkok, Thailand, 3 Department of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand, 4 Department of Medicine (Infectious Diseases), Albert Einstein College of Medicine, Bronx, New York, United States of America, 5 Department of Medicine, Division of Infectious Diseases, Memorial Sloan Kettering Cancer Center, United States of America, 6 Department of Medicine, Weill Cornell Medical College, Cornell University, New York, United States of America, 7 Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

* syoungchim@gmail.com

Abstract

*Talaromyces marneffei* is a thermally dimorphic fungus that causes opportunistic systemic mycoses in patients with AIDS or other immunodeficiency syndromes. The purpose of this study was to develop an immunochromatographic strip test (ICT) based on a solid phase sandwich format immunoassay for the detection of *T. marneffei* antigens in clinical urine specimens. The *T. marneffei* yeast phase specific monoclonal antibody 4D1 (MAb4D1) conjugated with colloidal gold nanoparticle was used as a specific signal reporter. *Galanthus nivalis* Agglutinin (GNA) was adsorbed onto nitrocellulose membrane to serve as the test line. Similarly, a control line was created above the test line by immobilization of rabbit anti-mouse IgG. The immobilized GNA served as capturing molecule and as non-immune mediated anti-terminal mannose of *T. marneffei* antigenic mannoprotein. The MAb4D1–GNA based ICT showed specific binding activity with yeast phase antigen of *T. marneffei*, and it did not react with other common pathogenic fungal antigens. The limit of detection of this ICT for *T. marneffei* antigen spiked in normal urine was approximately 0.6 μg/ml. The diagnostic performance of the ICT was validated using 341 urine samples from patients with culture-confirmed *T. marneffei* infection and from a control group of healthy individuals and patients with other infections in an endemic area. The ICT exhibited 89.47% sensitivity, 100% specificity, and 97.65% accuracy. Our results demonstrate that the urine-based GNA–MAb4D1 based ICT produces a visual result within 30 minutes and that the test is highly specific for the diagnosis of *T. marneffei* infection. The findings validate the deployment of the ICT for clinical use.
Author summary

Talaromycosis (Penicilliosis marneffei) is a neglected disease that causes an opportunistic systemic mycoses in AIDS and other immune-deficient patients living in Southeast Asia, China and the Indian subcontinent. Although laboratory culture remains a gold standard diagnostic method, it lacks sensitivity and is time-consuming, which results in delayed patient’s treatment and needed care. In this study, we develop an immunochromatographic strip test (ICT) by utilizing a yeast phase specific monoclonal antibody 4D1 and Galanthus nivalis agglutinin for detection of \( T. \) marneffei antigens in clinical urine specimens. Our data showed that the assay exhibited high sensitivity (89.47%) and specificity (100%), with its result available within 30 minutes. In addition, this diagnostic assay is inexpensive, reproducible, and simple to perform. Therefore, the \( T. \) marneffei ICT should be considered for clinical application in the context of rapid and affordable point-of-care diagnostic test to reduce the burden of talaromycosis mortality in patients in low resource countries.

Introduction

The thermally dimorphic fungus Talaromyces marneffei (previously Penicillium marneffei) causes disseminated mycosis affecting immunocompromised patients living in endemic areas including Southeast Asia, China and the Indian subcontinent [1,2]. In Thailand and Hong Kong, the prevalence of talaromycosis (penicilliosis marneffei) is surpassed only by that of tuberculosis, cryptococcosis and pneumocystis pneumonia [3,4]. Although advanced HIV disease is a well-documented risk factor for talaromycosis, the disease is increasingly reported among patients with other immune defects [5,6].

In the context of clinical laboratory diagnosis, \( T. \) marneffei is usually diagnosed by microscopic identification of the fungus in various clinical specimens and by standard microbiological culture, based on its morphological characteristics and thermally dimorphic properties between 25°C (mycelium form) and 37°C (yeast form). However, these procedures are relatively time-consuming, requiring about 3-14 days [7,8], which can negatively affect clinical decisions and delay the initiation of appropriate therapy. Thus, a “rapid point of care diagnosis” for \( T. \) marneffei infection is highly desirable, particularly if it could be inexpensive and provide a favorable limit of detection and have high precision and accuracy [9–12]. Ning et al., (2018) systematically reviewed and meta-analyzed the accuracy and diagnostic performance of rapid diagnostics for \( T. \) marneffei (RDTM) previously reported in the literature. They concluded that immunological based methods had high specificity and could potentially be classified for RDTM. However, false-negative or false positive results of these tests were often encountered [13].

Several previous studies have demonstrated that a yeast phase specific monoclonal antibody 4D1 (MAB 4D1; murine IgG1 isotype) is highly specific to the cytoplasmic yeast antigen of \( T. \) marneffei. MAB 4D1 recognizes a 50-180 kDa of N–linked glycoprotein and does not react with other medically important fungal antigens, including the mycelial phase cytoplasmic antigens of \( T. \) marneffei [14–17]. MAB 4D1 has previously been utilized in an inhibition enzyme-linked immunosorbent assay (Inh-ELISA) [15] and in an inhibition lateral flow immunochromatographic strip test (Inh-ICT) [16]; however, the Inh-ICT gave relatively low diagnostic sensitivity and occasional ambiguity in the reading and interpretation of the observed results (personal communication).
In the present study, we developed a lectin–antibody sandwich ELISA using a mannose binding lectin, which recognizes mannose residue called *Galanthus nivalis* agglutinin (GNA) or snowdrop lectin, in conjunction with MAb 4D1. GNA is an agglutinin that is known for its specific binding capacity to α-1,3 terminal mannose residues of oligosaccharides as well as mannoproteins [18,19]. We optimized the conditions for the GNA-MAb 4D1 sandwich ELISA to create a novel sandwich lateral flow immunochromatographic (ICT) strip. The ICT utilizes MAb 4D1 conjugated to 60 nm of gold colloid particle was used as a specific signal generating agent and the carbohydrate binding protein (GNA), immobilized at the test line zone, was used to capture the terminal mannose of *T. marneffei* antigen. Urine from talaromycosis patients and controls were used to test the efficacy of the ICT. The diagnostic performances of the novel sandwich ICT were validated in comparison to that of microbiological culture-confirmed talaromycosis marneffei, which is used as the gold standard laboratory diagnosis of *T. marneffei* infection.

**Materials and methods**

**Ethics statement**

The study was approved by the Research Ethics Committee of Faculty of Medicine, Chiang Mai University (approval number MIC-2561-05616/5616), and was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). All clinical samples investigated in this study were obtained from an existing sample collection. All samples were anonymized.

**Fungal isolates**

*T. marneffei* ATCC 200051, previously isolated from a bone marrow of AIDS patient at Chiang Mai University Hospital, Chiang Mai, Thailand, was used for all experiments in both the mycelial form and yeast form. The *T. marneffei* isolate was maintained by monthly subculture onto Potato Dextrose Agar (PDA; Difco). *T. marneffei* was grown on PDA for 7 days at 25˚C. Other fungal isolates were obtained and cultivated according to the directions from the American Type Culture Collection (ATCC) or from Department of Medical Services, Ministry of Public Health, Bangkok, Thailand. The fungal strains used this work are summarized in Table 1.

**T. marneffei** cytoplasmic yeast antigen (TM CYA) extraction

TM CYA extraction was carried out as described [15,20]. Briefly, 5x10^6 conidia/ml of *T. marneffei* was cultured in brain heart infusion broth (BHI; Difco) and incubated with a shaking incubator at 37˚C for 7 days. After killing with 0.02% (w/v) Merthiolate (Sigma) at room temperature for overnight, the yeast cells were harvested by centrifugation at 4,500 rpm for 10 minutes and mechanically broken with 0.5-mm glass Ballotini beads (BioSpec, Inc.) in a homogenizer (BioSpec, Bartlesville, OK, USA). After that, the protease inhibitor cocktails including iodoacetic acid (IAA; Sigma), phenylmethanesulfonyl fluoride (PMSF; Sigma), and EDTA were added to the homogenizer chamber to give final concentrations of 10 μM, 0.1 mM, and 1 mM, respectively. The homogenate was then centrifuged at 10,000 rpm for 30 minutes at 4˚C and the cytoplasmic antigen solution was decanted from the mixture supernatant. The cytoplasmic antigens in yeast or mycelial phase of other human pathogenic fungi were also prepared following this standardized procedure. The fungal protein concentrations of the individual preparations were determined using the Coomassie Brilliant Blue G-250 binding method (Bio-Rad Labs, Hercules, CA, USA) [21].
Purification of monoclonal antibody 4D1 (MAb4D1)

The murine-derived hybridoma cell line clone 4D1, IgG1 isotype, was maintained in serum free medium (Gibco), and purified by HiTrap column protein G affinity chromatography (GE Healthcare) as described [16]. The purity of the IgG fraction was validated by 10% SDS-PAGE. The concentrations of purified MAb 4D1 were determined by molar extinction coefficient at 280 nm of purified IgG (1.36 for a solution of 1 mg/ml) [22]. The immunoreactivity of MAb 4D1 was confirmed using indirect ELISA and Western blotting [15].

Standardization of GNA-MAb 4D1 sandwich ELISA for detection of TM CYA and other pathogenic fungal antigen

A sandwich ELISA using MAb 4D1 and GNA lectin to capture the terminal mannose residues of TM CYA was utilized to standardize and optimize the detection of TM CYA (Fig 1.) Purified GNA lyophilized powder from *G. nivalis* (snowdrop) bulbs (Sigma) was solubilized according to the manufacturer’s instructions.

**Incubation plate.** A 96 well U bottom microplate (Nunc A/S, Kamstrup, Denmark) was treated with 200 μl of 1.5% (w/v) BSA (Sigma) in phosphate buffer saline (PBS) pH 7.2 and incubated at 37°C for 60 minutes. Thereafter, the plate was washed five times with 0.05% Tween 20 in phosphate buffer saline pH 7.2 (PBST). Fifty μl of TM CYA or other pathogenic fungal antigen (at concentrations from 50–0.2 μg/ml) in diluting buffer (0.1% w/v BSA in PBST) was added to the BSA treated wells. Subsequently, an equal volume of MAB 4D1 (1.5 μg/ml) was added to each well and the plate was incubated on a shaker at 25°C for 30 minutes at 250 rpm, and then incubated at 4°C overnight to enable the formation of MAB 4D1–TM CYA immune complex.
Reaction plate. Fifty μl of 5 μg/ml purified GNA in 0.06 M carbonate coating buffer pH 9.6 was immobilized to wells of Maxisorp 96-well microtiter plates (Nunc A/S) by incubation overnight at 4˚C. Unbound GNA was removed by washing. BSA (1.5% w/v) in PBST was added and the plate was incubated at 37˚C for 60 minutes. Then, the plate was washed five times with PBST. Aliquots (50 μl) of the contents of each well in the incubation plate (containing a mixture of MAb4D1–TM CYA or other pathogenic fungal antigen) were transferred to respective wells in the reaction plate and allowed to react with the immobilized GNA for 60 minutes at 25˚C. The plate was washed again and HRP conjugated goat anti-mouse IgG antibody (Jackson, West Grove, PA, USA) diluted 1:10,000 in diluting buffer was added to each well followed by 60 minute incubation. After washing, H₂O₂/TMB substrate (BioFX Laboratories, SurModics IVD, Eden Prairie, MN, USA) was added and the enzymatic reaction was allowed to take place for 20 minutes at room temperature in the dark. The reaction was terminated by adding 2N H₂SO₄. The OD₄₅₀ was measured against a reference at OD₅₇₀ on an ELISA plate reader (Shimadzu model UV-2401PC, Kyoto, Japan). The test was performed in triplicates.

Principle and generation of the GNA-MAb 4D1 sandwich ICT strip for the detection of TM CYA

(I) Principle of assay format. The sandwich ICT format was applied to detect *T. marneffei* antigens in urine samples. MAb 4D1–colloidal gold conjugate was used to generate an assay signal. GNA was immobilized on the test line and rabbit anti-mouse IgG was immobilized on the control line of the micro-porous analytical nitrocellulose membrane. The ICT starts with an absorbing pad that enables the specimen to move along the strip via capillary tension to rehydrate the MAb 4D1–CG conjugate, which then will flow across the sample application pad. When *T. marneffei* antigen is present in the specimen, *T. marneffei* antigen will bind to
the MAb 4D1–CG conjugate and will be captured by the GNA immobilized at the test line (T). This establishes a colored test line and represents a positive result. If the T. marneffei antigen is absent or below the cut-off point (lower than the limit of detection), there is no visible colored at the test line (T), and this represents a negative result. As an internal control, immobilized rabbit anti mouse IgG reacts with the MAb 4D1-CG conjugate to form a control line (C), indicating that the assay has been performed properly (Fig 2).

(II) Preparation of colloidal gold nanoparticle - MAb 4D1 signal generator. MAb 4D1-colloidal gold (MAb 4D1–CG conjugate) is the signal generator used for the detection of T. marneffei antigens in clinical samples. MAb 4D1 was conjugated to CG particle (60 nm in diameter) by isoelectric point dependent passive adsorption [23]. An aliquot (0.6 ml) of CG suspension (Arista, Allentown, PA, USA) was adjusted to pH 9.0 with 0.1 M Na$_2$CO$_3$. Purified MAb 4D1 in deionized water (final concentration 7 μg/ml) was added to each well of the CG suspension and gently mixed for 60 minutes at room temperature. The unoccupied surface of the CG particle was blocked with 60 μl of 5% (w/v) casein (Sigma) dissolved in 2 mM Na$_2$B$_7$O$_4$ pH 9.0 for 15 minutes. The MAb 4D1–CG conjugate was centrifuged at 10,000 rpm at 4°C for 15 min and the supernatant was discarded. A suspension buffer of MAb 4D1–CG conjugate [0.5% (w/v) of casein, 20% (w/v) of sucrose (Sigma) dissolved in 2 mM Na$_2$B$_7$O$_4$ pH 9.0] was added, and the MAb 4D1–CG conjugates were centrifuged again under the same procedures. After removing the supernatant, the final volume of each aliquot was adjusted to 0.1 ml with MAb 4D1–CG conjugate suspension buffer. To produce the conjugate releasing pads, MAb 4D1–CG conjugate suspensions (5 μl) were individually applied onto a 0.4 x 0.5 cm glass fiber piece (Whatman Schleicher & Schuell, Dassel, Germany) and then heated in a 37˚C incubator for 60 minutes. The conjugate releasing pads were further dried in a 30% dehumidifier cabinet overnight before being assembled into the ICT strip system.

(III) Establishment of test line and control line onto analytical nitrocellulose membrane. Immobilizations of the GNA and the internal isotype antibody control (rabbit anti-mouse IgG, Sigma) onto the analytical nitrocellulose membranes were established by the physical adsorption in their respective line patterns using a BioDot17x100TM (BioDot, Irvine, CA, USA) dispensing platform. The rate of injection was adjusted to 1 μl/cm. The nitrocellulose membrane (AE99; Whatman Schleicher & Schuell) was sprayed at the test line with purified GNA (10 mg/ml diafiltered in 10 mM sodium phosphate buffer containing 10 mM sodium chloride pH 7.0) and rabbit anti-mouse IgG (0.5 mg/ml in 10 mM sodium phosphate buffer pH 7.0) was dispensed to the control line. The immobilized nitrocellulose membrane was immediately dried in 30% dehumidifier cabinet for 60 minutes. Then, the nitrocellulose membrane was blocked by submersion into blocking reagent [0.5% (w/v) of casein, 0.5% (w/v) of sucrose and 0.2% (w/v) of trehalose (Sigma) dissolved in 10 mM sodium phosphate buffer pH 7.4]. The blocked nitrocellulose membranes were then dried in a dehumidifier cabinet for 60 minutes and stored at room temperature for 24 hours before being assembled into the ICT strip system.

(IV) Preparation of the sample application pad. The sample application pad used in the ICT construction was prepared by pre-treatment of the 903 specimen collection paper (Whatman Schleicher & Schuell, Dassel, Germany) with a mixture solution of 2% (v/v) Triton X-100 (Sigma) and 0.05% (w/v) of polyvinylpyrrolidone (Sigma) dissolved in 50 mM Tris-HCl, pH 7.4 and then the pad was dried in a 30% dehumidifier cabinet overnight [24].

(V) Assembly and production of individual ICT strip. The ICT strip was assembled utilizing 4 major components: (i) the GNA and isotype controlled antibody immobilized nitrocellulose membrane (NC), (ii) the treated sample application pad (SP), (iii) the impregnated conjugate releasing pad (CRP) and (iv) the wicking pad or WP (3 MM chromatography paper, Whatman, Maidstone, England). The components were manually assembled and held permanently in place with a laminating backing card (Self-adhesive polyester backing, Schleicher &
The assembled cards were then individually cut into 0.4 cm wide and 10 cm long strips using a BioDot CM 4000 R guillotine cutter (BioDot, Irvine, CA, USA). The schematic of the ICT strip is detailed in Fig 3.

Fig 2. The cartoon formats of GNA–MAb 4D1 sandwich ICT strip for rapid detection of *T. marneffei* antigen from a clinical sample. (A), the schematic presentation of the positions where MAb 4D1, GNA and rabbit anti-mouse IgG antibodies are immobilized in an analytical nitrocellulose membrane. (B), the reactions that occur on the MAb 4D1 – GNA strip in the presence of *T. marneffei* antigen and (C), in the absence of *T. marneffei* antigens. The red–purple color of colloidal gold conjugate appears at the test line and/or control line, depending on the presence of *T. marneffei* in the clinical sample.

https://doi.org/10.1371/journal.pntd.0009058.g002

Schuell). The assembled cards were then individually cut into 0.4 cm wide and 10 cm long strips using a BioDot1 CM 4000 R guillotine cutter (BioDot, Irvine, CA, USA). The schematic of the ICT strip is detailed in Fig 3.
Detection of *T. marneffei* antigen by the GNA-MAb 4D1 sandwich ICT strip

Urices were aliquoted (150 μl) into a 96-well U shape microtiter plate. ICT strips were dipped vertically with the sample application pad placed into urine specimens. If *T. marneffei* antigen was present in the sample, bands formed in both the test line (*T. marneffei* antigen, GNA and conjugated MAb 4D1) and the control line. Negative result will show only one band (Rabbit anti-mouse IgG and conjugated MAb 4D1) at the control line. Using direct visualization of bands as readout, the results of the ICT were available within 30 minutes, as determined by independent observations by three experienced laboratory technicians.

Determination of the lower limit of detection (LOD) and cross reactivity of the GNA-MAb 4D1 sandwich ICT strip

The ICT strip test was used to detect various concentrations of TM CYA in pooled urines from healthy individuals living in an endemic area (Chiang Mai and Bangkok, Thailand). Urines from healthy individuals were spiked with TM CYA to give final TM CYA concentrations of 0.31, 0.62, 1.25, 2.5, 5 and 10 μg/ml. Spiked and non-spiked control urine solutions (150 μl) were pipetted into the microtiter plates. The ICT strips were dipped into the urines, and the visual results were recorded at 30 minutes. The signal intensity of the test lines and control line were also scanned using the Chemidoc-It2, UVP, LLC, Canada and the band intensity was quantified by image J software (version 1.49) [16]. The limit of detection of the test was reported as the lowest concentration of TM CYA that gave a positive signal.

To evaluate the cross reactivity of the ICT, spiked urines from healthy individuals with cytoplasmic proteins (10 μg/ml) derived from different pathogenic fungi were tested. In addition to protein antigens, glucuronoxylomannan (GXM) polysaccharide capsular antigen of *C. neoformans* serotype A, strain H99 was purified as described [25] and urine was spiked with this material (10 μg/ml) and tested by the ICT.
Clinical samples, Healthy urine samples and Sample size calculation

The diagnostic performances of the ICT strip were evaluated in clinical urine. The urine specimens from HIV-seroreactive patients with culture confirmed *T. marneffei* infections were collected between September 2004 to September 2019 (n =76) at the clinical pathology unit, Chiang Mai University Hospital, Chiang Mai, Thailand. The urine samples were obtained at the time of diagnosis and stored at -80°C until they were thawed immediately prior to investigation. For the non-*T. marneffei* infected control group, urine samples from patients infected with other pathogenic microorganisms (fungus, virus, bacteria and parasites) as well as from healthy individuals living in an endemic area were also selected from our stored urine collection and tested (Table 2).

The sample sizes were estimated based on matched case-control studies [26]. The optimized parameter was then determined using the following formula:

\[
 n = \frac{Z^2_{1-\alpha} (\hat{P} \hat{Q})}{e^2}
\]

The minimum acceptable sampling size was 68 cases in both talaromycosis (case) and nontalaromycosis (control) when calculated without the dropout rate. However, regard to the dropout rate was defined as 10%, the minimum acceptable sampling size was 76 cases in both cases and controls.

Validation of diagnostic performance of the GNA-MAb 4D1 sandwich ICT strip and statistical analysis

Various variables were studied using the number of case-control samples in comparison to the gold standard method, which included the number of true-positive results (TP), the true-negative results (TN), the false-positive results (FP), and the false-negative results (FN). The McNemar’s test for a case-control study was used to calculate the diagnostic sensitivity, specificity and accuracy with their 95% confidence intervals (95% C.I.). Moreover, the consistencies between different tests were determined by Cohen’s kappa coefficient of agreement using GraphPad (QuickCalcs Program, San Diego, CA), which was interpreted according to the kappa statistic values of > 0.81, 0.41 to 0.80, or < 0.40 indicating almost perfect agreement, moderate to substantial agreement, and slight to fair or poor agreement, respectively [27].

Results

Detection of TM CYA and other pathogenic fungal antigen by the GNA–MAb 4D1 sandwich ELISA

The GNA–MAb 4D1 sandwich ELISA format was established to capture the target antigenic mannoprotein in crude extracted of TM CYA (Fig 1). As expected, the bi-functional GNA–MAb 4D1 was selectively reactive against TM CYA, with no detectable reactivity toward other pathogenic fungal antigens as well as *T. marneffei* mycelial antigen (TM CMA). For the TM

Table 2. Clinical urine samples used in the present study.

| Clinical urine samples                          | Total |
|------------------------------------------------|-------|
| Gold standard confirmed of *T. marneffei*      | 76    |
| Other pathogenic microorganism infection (Identified in supplemented Table 1) | 184   |
| Normal healthy from endemic area               | 81    |
| **Total**                                       | **341** |

https://doi.org/10.1371/journal.pntd.0009058.t002
CYA reaction, the limit of detection (LOD) for the standardized sandwich ELISA using GNA–MAb 4D1 was 0.8 μg/ml of TM CYA using an OD 450 nm cut off at 0.250. Moreover, the experimental controls confirmed that GNA alone did not recognize either MAb 4D1 or HRP conjugated goat anti-mouse IgG antibody. Therefore, the positive reaction only occurred when TM CYA was present in the ELISA reaction (Fig 4).

Development of the GNA-MAb 4D1 sandwich ICT strip for the detection of TM CYA

A sandwich ICT strip for the detection of TM CYA was developed using GNA directly immobilized onto the analytical nitrocellulose membrane with the MAb 4D1-CG conjugate serving as the signal reporter. The specific reaction of TM CYA and MAb 4D1-CG conjugate resulted in the formation of a visible purple immune complex on the test line of the nitrocellulose membrane. The excess MAb 4D1-CG conjugate moved further to the control line which served to verify the validity of the assay (Fig 5).

Limit of detection (LOD) of the GNA-MAb 4D1 sandwich ICT strip

The lower limit of detection of this assay ICT strip was investigated with the urine from normal healthy volunteers spiked with various concentration of TM CYA. Direct visualization found that the LOD for the ICT was 0.62 μg/ml of TM CYA and the readout was achieved within 30 minutes. The LOD of this assay was also quantified and interpreted with the Chemidoc-It2 UVP scanner and image J software (version 1.49). The test line band intensity
gradually decreased in a dose-response manner of spiked TM CYA, and the digital methodology produced a similar result to what was achieved with direct visualization (Fig 6).

Cross reactivity of the GNA-MAb 4D1 sandwich ICT strip

To investigate the specificity of the sandwich ICT, TM CMA as well as crude antigenic proteins extracted from common fungal pathogens (Table 1) were spiked into urine from normal healthy volunteers at a final concentration of 10 μg/ml (equal to the maximum concentration of TM CYA). The sandwich ICT strip was highly specific to TM CYA; the results showed an absence of cross-reactivity, even with the T. marneffei mycelial extracts, TM CMA (Fig 7). Although this assay gave only qualitative results, these results were agreement with those obtained from GNA-MAb 4D1 sandwich ELISA.

Detection of T. marneffei antigenuria by the GNA-MAb 4D1 sandwich ICT strip and diagnostic performance

The diagnostic performance of the sandwich GNA-MAb 4D1 sandwich ICT strip was further conducted using 341 urine samples obtained from patients infected with T. marneffei or other
infections as well as from normal healthy controls. For the 76 confirmed talaromycosis cases, 68 urine samples produced positive ICT results and 8 samples were false negatives. For the control cases, all 265 non–*T. marneffei* urine samples were negative by ICT. Among the 265 non–*T. marneffei* urine samples, 81 were from normal healthy subjects living in an endemic area (Table 3). The remaining 184 samples were identified as infected with other pathogenic microorganism or they had other underlying diseases associated with immune system impairment (S1 Table).

The diagnostic performances of the GNA-MAb 4D1 sandwich ICT was in concordance with the results from culture confirmed talaromycosis. The sandwich ICT strip exhibited a diagnostic sensitivity, specificity and accuracy of 89.47% (95% C.I.; 80.31–95.34), 100% (95% C.I.; 98.62–100) and 97.65% (95% C.I.; 95.43–98.98), respectively. The Cohen’s kappa coefficient analysis was 0.930 (95% C.I.; 0.882–0.978) for the samples assayed by the two different diagnostic techniques, indicating ‘almost perfect agreement’ between the novel sandwich ICT and the gold standard diagnosis of talaromycosis (microbiological culture) [27] (Table 4).

**Study on the interference of non–*T. marneffei* mannans with the GNA-MAb 4D1 sandwich ICT**

Since GNA recognizes the terminal mannose residues of fungal antigen, we considered the possibility that mannan released by other fungi in patients co–infected with *T. marneffei* could affect the performance of the ICT. For example, infections with both *T. marneffei* and C.
*C. neoformans* occur in both HIV and non-HIV associated talaromycosis [28–30]. To investigate the possible interference of the major mannann produced by *C. neoformans*, the capsular polysaccharide antigen GXM, we spiked *T. marneffei* positive urine spiked with different concentrations (1,000–31.25 ng/ml) of purified GXM, as previous studies report that GXM concentrations in the urine of cryptococcosis patients are approximately 170 ng/ml [31]. We found that the presence of GXM did not alter the performance of the ICT (Fig 8). To confirm the presence of GXM in the spiked urine, we performed our in-house ICT strip for *C. neoformans* capsular antigen (Fig 8H) [32].

---

**Fig 7. Specificity of the GNA-MAb 4D1 sandwich ICT strip.** Normal urine samples from healthy individuals were spiked with various pathogenic fungal antigens at 10 ng/ml. A, TM CYA (served as a positive control); B, normal healthy urine sample (served as a negative control); C, S. schenckii CYA; D, H. capsulatum CYA; E, C. neoformans GXM; F, C. albicans; G, C. glabrata; H, P. insidiosum; I, A. fumigatus; J, P. citrinum; K, P. chrysogenum; L, P. boydii; M, C. krusei; N, Trichosporon spp.; O, Geotrichum spp.; and P, TM CMA. Abbreviations: CYA, Cytoplasmic Yeast Antigen; CMA, Cytoplasmic Mycelium Antigen C, control line; T, test line.

https://doi.org/10.1371/journal.pntd.0009058.g007
Discussion

*T. marneffei* opportunistically occurs in patients with secondary immunodeficiency syndromes, especially in patients with advanced HIV infection or other diseases associated with cellular immunity impairment [17]. In order to improve the outcomes for patients and to facilitate the earlier administration of appropriate antifungal medications, laboratory diagnosis of talaromycosis must be accurate and rapid. The definitive diagnosis for talaromycosis relies on the direct culture of the fungus from a variety of clinical samples, and it is based on fungal morphology and thermally dimorphism properties [1]. This procedure is time-consuming, which may delay the diagnosis of this systemic mycosis, resulting in delays treatment and increases in mortality. Other clinical microscopic diagnostic approaches based on pathological staining (e.g., Hematoxylin and Eosin (H&E), Gomori methenamine silver (GMS) and Periodic acid–Schiff (PAS) staining have been applied to various types of clinical samples including skin scraping, bone marrow and lymph nodes [33]. However, such methods have important limitations since the microscopic morphology of *T. marneffei* yeast-like cells are extremely similar to other intracellular pathogen such as *H. capsulatum*, *Pneumocystis jirovecii* as well as *Leishmania donovani* [34]. Additionally, tissue processing and these staining techniques can be time intensive.

The rapid diagnostic methods for talaromycosis available to date do not have adequate diagnostic sensitivity, specificity, and accuracy. Although molecular methods e.g., polymerase chain reaction (PCR) based assays, mainly real-time quantitative PCR [35] and nested PCR [36] have been established, the diagnostic sensitivities of PCR based assays are insufficient (range 60-70%). Also, such molecular methods remain impractical for the point of care testing as they are relatively expensive and they require sophisticated instruments and skilled laboratory personnel [12,17]. Therefore, simpler, faster tests with higher sensitivity and specificity are required, and rapid immunological-based methods constitute a rational approach to achieve this goal.

Currently, there is no commercially available rapid immunodiagnostic test for *T. marneffei*. There has been interest in utilizing the detection of galactomannans (GM) by the Plateria Aspergillus EIA [37,38]; however, significant false positive occur [17], which is not surprising given that GM is produced by a variety of fungi commonly encountered in areas where

| Table 3. Two by Two table analysis of diagnostic performance of GNA-MAb 4D1 sandwich ICT strip. |
|-------------------------------------------------|
| Sandwich ICT strip results | Gold standard confirmed Talaromycosis | Total |
| Positive | Negative |  |  |
| Positive | 68 (TP') | 0 (FP') | 68 |
| Negative | 8 (FN') | 265 (TN') | 273 |
| Total | 76 | 265 | 341 |

*TP, True Positive; TN, True Negative; FP, False Positive; FN, False Negative

https://doi.org/10.1371/journal.pntd.0009058.t003

| Table 4. Summary of diagnostic performance of GNA-MAb 4D1 sandwich ICT strip. |
|-------------------------------------------------|
| Diagnostic performance criteria | Percentages (95% C.I.) |
| Sensitivity | 89.47 (80.31–95.34) |
| Specificity | 100 (98.62-100) |
| Accuracy | 97.65 (95.43–98.98) |
| Cohen’s kappa coefficient (κ) | 0.930 (0.882-0.978) |

https://doi.org/10.1371/journal.pntd.0009058.t004
Talaromycosis occurs, including Aspergillus spp., Penicillium spp., Paecilomyces spp., Purpureocillium licacinum, Histoplasma spp., and Cryptococcus spp. [39,40].

We have previously demonstrated the specificity of MAb 4D1 for TM CYA [14–17]. Our prior Inh-ELISA [15] and Inh-ICT [16] have demonstrated the utility of MAb 4D1 in immunodiagnostic strategies. We have now incorporated colloidal gold nanoparticle-conjugated MAb 4D1 and GNA in the development of an inexpensive, user-friendly and efficient ICT for the visual detection of T. marneffei antigen in urine within 30 minutes. In general, carbohydrate binding proteins or lectins (often called agglutinins) are ubiquitous proteins of non-immune origin. They are extracted from plants, microorganisms, animals; and interact specifically and reversibly with defined monosugars or oligosaccharide structures in accordance with the lock and key model [41,42]. Multiple applications of lectins in the field of biological research, both as reagents and clinical diagnostic tools have been frequently reported [43,44].

For the diagnostic performance of the ICT, sensitivity, specificity, and accuracy of the assay were 89.47%, 100%, and 97.65% respectively. However, since approximately 76% of patients with T. marneffei infections have positive blood cultures [7,45], it is possible that the sensitivity of this ICT strip might be lower in urine from hemoculture negative talaromycosis due to a lower level of T. marneffei antigen in urine. However, antigens are frequently detected in the urine by immunodiagnostic methods in histoplasmosis patients without fungemia [46,47]; hence, further testing is required to determine the efficacy of the T. marneffei ICT in various conditions.

Fig 8. The effect of non-T. marneffei mannan interference with GNA-MAb 4D1 sandwich ICT strip. T. marneffei positive urine was spiked with various concentrations of GXM of C. neoformans (serotype A). A: T. marneffei positive urine, B–G labels indicated the concentrations of C. neoformans GXM from 1,000, 500, 250, 125, 62.5, and 31.25 ng/ml respectively, were spiked in T. marneffei positive urine. H: to confirm GXM presence in urine, in-house sandwich ICT strip was established for detecting C. neoformans capsular antigen at the GXM concentration of 31.25 ng/ml.

https://doi.org/10.1371/journal.pntd.0009058.g008
clinical settings. We unfortunately do not have the clinical information for the 8 false negative cases, which would potentially provide important information on the limitations of the ICT. It is possible that these individuals were either early in their disease process or were already undergoing antifungal drug treatment. The latter is very important as the ICT may be able to guide therapy. As the differential band intensity in Fig 6 is directly associated with the concentration of TM CYA in urine, it may be possible to derive quantitative results using a standardized readout with a biosensor-based machine [48]. Hence, the ICT could define changes in antigen concentration over time, which may correlate with the efficacy of treatment [15,49]. However, the simplicity of interpreting the strips by visual assessment means that the ICT is highly appropriate for utilization in under resourced regions, such as in rural communities, to facilitate an early diagnosis.

It is important to consider the application of the ICT for testing other clinical body fluids. Unfortunately, our ICT strip system cannot be used with serum samples; the physical matrix of serum interferes with the colloidal gold conjugate and leads to the deterioration of colloidal gold and fluid obstruction. When we tested the ICT strip with talaromycosis serum, the diagnostic sensitivity was reduced to 71.43% (15/21). In the future, we may have the opportunity to investigate the efficacy of the ICT system with other body fluids, such as bronchoalveolar lavage or cerebral spinal fluid [50,51].

In conclusion, the GNA-MAb 4D1 sandwich ICT strip is a novel rapid lateral flow diagnostic test that effectively identifies T. marneffei antigen in clinical urine samples. The assay is inexpensive, reproducible, and extremely easy to perform. As results are available within 30 minutes, the T. marneffei ICT may facilitate a substantially earlier diagnosis of T. marneffei infection before the results of other currently applied method are available. Therefore, we recommend that the T. marneffei ICT strip should be considered for clinical application in the context of rapid diagnosis for talaromycosis.

Supporting information

S1 Table. Urine samples of non–talaromycosis group.

(DOCX)

Acknowledgments

The authors are deeply grateful to Associate Professor Dr. Nitat Sookrung and Ms. Pisinee Aiumurai from Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, for the valuable suggestions and assistance. We would like to thank Mr. Kittikun Kittidachanan from the Department of Radiology, Faculty of Medicine, Chiang Mai University, for the kindly assistance in statistical analysis.

Author Contributions

Conceptualization: Kritsada Pruksaphon, Joshua D. Nosanchuk, Sirida Youngchim.

Data curation: Kritsada Pruksaphon, Sirida Youngchim.

Formal analysis: Kritsada Pruksaphon, Akarin Intaramat, Pavinee Simsiriwong, Sirida Youngchim.

Funding acquisition: Akarin Intaramat, Sirida Youngchim.

Investigation: Skorn Mongkolsuk, Sirida Youngchim.
Methodology: Kritsada Pruksaphon, Akarin Intaramat, Pavinee Simsiriwong, Kavi Ratanabanangkoon.

Project administration: Sirida Youngchim.

Resources: Skorn Mongkolsuk, Sirida Youngchim.

Software: Akarin Intaramat, Pavinee Simsiriwong.

Supervision: Kavi Ratanabanangkoon, Joshua D. Nosanchuk, Sirida Youngchim.

Validation: Kritsada Pruksaphon, Akarin Intaramat.

Visualization: Kritsada Pruksaphon, Kavi Ratanabanangkoon, Joshua D. Nosanchuk, Anna Kaltsas.

Writing – original draft: Kritsada Pruksaphon, Kavi Ratanabanangkoon.

Writing – review & editing: Joshua D. Nosanchuk, Anna Kaltsas, Sirida Youngchim.

References

1. Vanittanakom N, Cooper CR Jr., Fisher MC, Sirisanthana T. *Penicillium marneffei* infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev. 2006; 19(1):95–110. Epub 2006/01/19. https://doi.org/10.1128/CMR.19.1.95-110.2006 PMID: 16418525

2. Sethuraman N, Thirunarayan MA, Gopalakrishnan R, Rudramurthy S, Ramasubramanian V, Parameswaran A. *Talaromyces marneffei* outside endemic areas in India: an emerging infection with atypical clinical presentations and review of published reports from India. Mycopathologia. 2020; 185(5):893–904. Epub 2020/01/03. https://doi.org/10.1007/s11046-019-00420-0 PMID: 31894499

3. Supparatpinyo K, Chiewchanvirat S, Hirunski P, Uthammachai C, Nelson KE, Sirisanthana T. *Penicillium marneffei* infection in patients infected with human immunodeficiency virus. Clin Infect Dis. 1992; 14(4):871–4. Epub 1992/04/01. https://doi.org/10.1093/clinids/14.4.871 PMID: 1315586.

4. Wong KH, Lee SS, Chan KC, Choi T. Redefining AIDS: case exemplified by *Penicillium marneffei* infection in HIV-infected people in Hong Kong. Int J STD AIDS. 1998; 9(9):555–6. Epub 1998/10/09. PMID: 9764944

5. Chan JF, Chan TS, Gill H, Lam FY, Trendell-Smith NJ, Sridhar S, et al. Disseminated infections with *Talaromyces marneffei* in non-AIDS patients given monoclonal antibodies against CD20 and kinase inhibitors. Emerg Infect Dis. 2015; 21(7):1101–6. Epub 2015/06/17. https://doi.org/10.3201/eid2107.150138 PMID: 26079984

6. Chan JF, Lau SK, Yuen KY, Woo PC. *Talaromyces* (*Penicillium*) *marneffei* infection in non-HIV-infected patients. Emerg Microbes Infect. 2016; 5(3):e19. Epub 2016/03/10. https://doi.org/10.1038/emi.2016.18 PMID: 26956447

7. Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated *Penicillium marneffei* infection in Southeast Asia. Lancet (London, England). 1994; 344(8915):110–3. Epub 1994/07/09. https://doi.org/10.1016/s0140-6736(94)91287-4 PMID: 7912350

8. Le T, Wolbers M, Chi NH, Quang VM, Chinh NT, Lan NP, et al. Epidemiology, seasonality, and predictors of outcome of AIDS-associated *Penicillium marneffei* infection in Ho Chi Minh City, Viet Nam. Clin Infect Dis. 2011; 52(7):945–52. Epub 2011/03/24. https://doi.org/10.1093/cid/cir288 PMID: 21427403

9. Drain PK, Hyle EP, Noubary F, Freedberg KA, Wilson D, Bishai WR, et al. Diagnostic point-of-care tests in resource-limited settings. Lancet Infect Dis. 2014; 14(3):239–49. Epub 2013/12/13. https://doi.org/10.1016/S1473-3099(13)70250-0 PMID: 24332389

10. Kozel TR, Burnham-Marusich AR. Point-of-Care Testing for Infectious Diseases: Past, Present, and Future. J Clin Microbiol. 2017; 55(8):2313–20. Epub 2017/05/26. https://doi.org/10.1128/JCM.00476-17 PMID: 28539345

11. Chastain DB, Henao-Martinez AF, Franco-Paredes C. Opportunistic invasive mycoses in AIDS: Cryptococcosis, Histoplasmosis, Coccioidiomycosis, and Talaromycosis. Curr Infect Dis Rep. 2017; 19(10):36. Epub 2017/08/24. https://doi.org/10.1007/s11908-017-0592-7 PMID: 28831671

12. Limper AH, Adenis A, Le T, Harrison TS. Fungal infections in HIV/AIDS. Lancet Infect Dis. 2017; 17(11):e334–e43. Epub 2017/08/05. https://doi.org/10.1016/S1473-3099(17)30303-1 PMID: 28774701
13. Ning C, Lai J, Wei W, Zhou B, Huang J, Jiang J, et al. Accuracy of rapid diagnosis of Talaromycosis marneffei: A systematic review and meta-analysis. PloS one. 2018; 13(4): e0195569. Epub 2018/04/06. https://doi.org/10.1371/journal.pone.0195569 PMID: 29621346

14. Rafferty K. Penicillium marneffei: immunological response to infection and development of novel diagnostic methods. King’s College London, University of London, UK; 2004.

15. Prakit K, Nosanchuk JD, Pruksaphon K, Vanittanakom N, Youngchim S. A novel inhibition ELISA for the detection and monitoring of Penicillium marneffei antigens in human serum. Eur J Clin Microbiol Infect Dis. 2016; 35(4):647–56. Epub 2016/02/04. https://doi.org/10.1007/s10096-016-2583-2 PMID: 26838686

16. Pruksaphon K, Intaramat A, Ratanabanangkoon K, Nosanchuk JD, Vanittanakom N, Youngchim S. Development and characterization of an immunochromatographic test for the rapid diagnosis of Talaromyces (Penicillium) marneffei. PloS one. 2018; 13(4):e0195596. Epub 2018/04/12. https://doi.org/10.1371/journal.pone.0195596 PMID: 29641620

17. Pruksaphon K, Intaramat A, Ratanabanangkoon K, Nosanchuk JD, Vanittanakom N, Youngchim S. Diagnostic laboratory immunology for talaromycosis (penicilliosis): review from the bench-top techniques to the point-of-care testing. Diagn Microbiol Infect Dis. 2020; 96(3):114959. Epub 2019/12/15. https://doi.org/10.1016/j.diagmicrobio.2019.114959 PMID: 31836254

18. Shibuya N, Goldstein IJ, Van Damme EJ, Peumans WJ. Binding properties of a mannose-specific lectin from the snowdrop (Galanthus nivalis) bulb. J Biol Chem. 1988; 263(2):728–34. Epub 1988/01/15. PMID: 3335522

19. Wright CS, Kaku H, Goldstein IJ. Crystallization and preliminary X-ray diffraction results of snowdrop (Galanthus nivalis) lectin. J Biol Chem. 1990; 265(3):1676–7. Epub 1990/01/25. PMID: 2299649

20. Jeavons L, Hamilton AJ, Vanittanakom N, Ungpakorn R, Evans EG, Sirisanthana T, et al. Identification and purification of specific Penicillium marneffei antigens and their recognition by human immune sera. J Clin Microbiol. 1998; 36(4):949–54. Epub 1998/05/23. https://doi.org/10.1128/JCM.36.4.949-954.1998 PMID: 9542914

21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248–54. Epub 1976/05/07. https://doi.org/10.1016/0003-2697(76)90573-8 PMID: 942051

22. Johnstone A, Thorpe R. “Immunoassays” in Immunochromatography in Practice. 2nd, editor: Blackwell Scientific Pub, London, UK; 1988.

23. Liu L, Yang D, Liu G. Signal amplification strategies for paper-based analytical devices. Biosens Bioelectron. 2019; 136:60–75. Epub 2019/04/30. https://doi.org/10.1016/j.bios.2019.04.043 PMID: 31035028

24. Intaramat A, Sompachtrum T, Chantrathong B, Chaisuriya P, Lohnoo T, Yingyong W, et al. Protein A/Liu L, Yang D, Liu G. Signal amplification strategies for paper-based analytical devices. Biosens Bioelectron. 2019; 136:60–75. Epub 2019/04/30. https://doi.org/10.1016/j.bios.2019.04.043 PMID: 31035028

25. Nimrichter L, Frases S, Cinelli LP, Viana NB, Nakouzi A, Travassos LR, et al. Self-aggregation of Penicillium marneffei: A systematic review and meta-analysis. PloS one. 2018; 13(4):e0195596. Epub 2018/04/12. https://doi.org/10.1371/journal.pone.0195596 PMID: 29641620

26. Dupont WD. Power calculations for matched case-control studies. Biometrics. 1988; 44(4):1157–68. https://doi.org/10.2307/2531743 PMID: 3233252

27. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33(1):159–74. Epub 1977/03/01. PMID: 843571

28. Le T, Hong Chau TT, Kim Cuc NT, Si Lam P, Manh Sieu TP, Shikuma CM, et al. AIDS-associated Cryptococcus neoformans and Penicillium marneffei coinfection: a therapeutic dilemma in resource-limited settings. Clin Infect Dis. 2010; 51(8):e65–8. Epub 2010/05/05. https://doi.org/10.1086/656685 PMID: 20887205

29. Zeng W, Qiu Y, Tang S, Zhang J, Pan M, Zhong X. Characterization of anti-interferon-γ antibodies in HIV-negative patients infected with disseminated Talaromyces marneffei and Cryptococcosis. Open Forum Infect Dis. 2019; 6(10):ofz208. Epub 2019/10/30. https://doi.org/10.1093/ofid/ofz208 PMID: 31660325

30. He S, Lv D, Xu Y, Wu X, Lin L. Concurrent infection with Talaromyces marneffei and Cryptococcus neoformans in a patient without HIV infection. Exp Ther Med. 2020; 19(1):160–4. Epub 2019/12/20. https://doi.org/10.3892/etm.2019.8172 PMID: 31853286

31. Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, Williams GN, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis. 2011; 53(10):1019–23. Epub 2011/09/24. https://doi.org/10.1093/cid/cir613 PMID: 21940419
32. Sathongdejwisit P. Rapid diagnosis of Cryptococcus neoformans infection by using specific monoclonal antibody 1887: Graduate School, Chiang Mai University, Chiang Mai, TH; 2020.

33. Guarnier J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev. 2011; 24(2):247–80. Epub 2011/04/13. https://doi.org/10.1128/CMR.00053-10 PMID: 21482725

34. Vivianni MA, Totorano AM. Penicillium marneffei. In Topley and Wilson’s Microbiology and Microbial Infection: Medical Mycology. Ajello L and Hey RJ (eds): Arnold, London, UK; 1998.

35. Hien HTA, Thanh TT, Thu NTM, Nguyen A, Thanh NT, Lan NPH, et al. Development and evaluation of a real-time polymerase chain reaction assay for the rapid detection of Talaromyces marneffei MP1 gene in human plasma. Mycoses. 2016; 59(12):773–80. Epub 2016/07/28. https://doi.org/10.1111/myc.12530 PMID: 27453379

36. Lu S, Li X, Calderone R, Zhang J, Ma J, Cai W, et al. Whole blood Nested PCR and Real-time PCR amplification of Talaromyces marneffei specific DNA for diagnosis. Med Mycol. 2016; 54(2):162–8. Epub 2015/10/16. https://doi.org/10.1093/mymyco/myw068 PMID: 26468550

37. Zheng J, Gui X, Cao Q, Yang R, Yan Y, Deng L, et al. A Clinical study of acquired immunodeficiency syndrome associated Penicillium marneffei infection from a non-endemic area in China. Plos one. 2015; 10(6):e0130376. Epub 2015/06/18. https://doi.org/10.1371/journal.pone.0130376 PMID: 26083736

38. Huang YT, Hung CC, Liao CH, Sun HY, Chang SC, Chen YC. Detection of circulating galactomannan in serum samples for diagnosis of Penicillium marneffei infection and cryptococcosis among patients infected with human immunodeficiency virus. J Clin Microbiol. 2007; 45(9):2858–62. Epub 2007/06/29. https://doi.org/10.1128/JCM.0050-07 PMID: 17596363

39. Terrero-Salcedo D, Powers-Fletcher MV. Updates in laboratory diagnostics for invasive fungal infections. J Clin Microbiol. 2020; 58(6):e01487–19. Epub 2020/03/07. https://doi.org/10.1128/JCM.01487-19 PMID: 32132194

40. Dalle F, Charles PE, Blanc K, Caillot D, Chavanet P, Dromer F, et al. Cryptococcus neoformans galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus galactomannan. J Clin Microbiol. 2005; 43(6):2929–31. Epub 2005/06/16. https://doi.org/10.1128/JCM.43.6.2929-2931.2005 PMID: 15956422

41. Kennedy JF, Palva PMG, Corella MTS, Cavalcanti MSM, Coelho L. Lectins, versatile proteins of recognition: a review. Carbohydr Polym. 1995; 26(3):219–30. https://doi.org/10.1016/0144-8617(94)00091-7

42. Dias Rde O, Machado Ldos S, Migliolo L, Franco OL. Insights into animal and plant lectins with antimicrobial activities. Molecules (Basel, Switzerland). 2015; 20(1):519–41. Epub 2015/01/09. https://doi.org/10.3390/molecules20010519 PMID: 25569512

43. Lee EY, Kang JH, Kim KA, Chung TW, Yoon DY, et al. Development of a rapid, immunochromatographic strip test for serum asialo alpha1-acid glycoprotein in patients with hepatic disease. J Immunol Methods. 2006; 308(1-2):116–23. Epub 2006/01/13. https://doi.org/10.1016/j.jim.2005.10.010 PMID: 16403512

44. Dan X, Liu W, Ng TB. Development and applications of lectins as biological tools in biomedical research. Med Res Rev. 2016; 36(2):221–47. Epub 2015/08/21. https://doi.org/10.1002/med.21363 PMID: 26290041

45. Kawila R, Chaivarith R, Supparatpinyo K. Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study. BMC Infect Dis. 2013; 13:464. Epub 2013/10/08. https://doi.org/10.1186/1471-2334-13-464 PMID: 24094273

46. Wheat LJ, Garringer T, Brizendine E, Connolly P. Diagnosis of histoplasmosis by antigen detection based upon experience at the histoplasmosis reference laboratory. Diagn Microbiol Infect Dis. 2002; 43(1):29–37. Epub 2002/06/08. https://doi.org/10.1016/s0732-8893(02)00367-x PMID: 12052626

47. Guimarães AJ, Nosanchuk JD, Zancopé-Oliveira RM. Diagnosis of histoplasmosis. Braz J Microbiol. 2006; 37:1–13. https://doi.org/10.1590/S1517-83822006000100001 PMID: 20445761

48. Urusov AE, Zherdev AV, Dzantiev BB. Towards Lateral Flow Quantitative Assays: Detection Approaches. Biosensors. 2019; 9(3):89. Epub 2019/07/20. https://doi.org/10.3390/bios9030089 PMID: 31319629

49. Miceli MH, Grazziutti ML, Woods G, Zhao W, Kocoglu MH, Barlogie B, et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008; 46(9):1412–22. Epub 2008/04/19. https://doi.org/10.1086/528714 PMID: 18419445

50. Le T, Huu Chi N, Kim Cuc NT, Manh Sieu TP, Shikuma CM, Farrar J, et al. AIDS-associated Penicillium marneffei infection of the central nervous system. Clin Infect Dis. 2010; 51(12):1458–62. Epub 2010/11/09. https://doi.org/10.1086/657400 PMID: 21054180
51. Li YY, Dong RJ, Shrestha S, Upadhyay P, Li HQ, Kuang YQ, et al. AIDS-associated *Talaromyces marneffei* central nervous system infection in patients of Southwestern China. AIDS Res Ther. 2020; 17(1):26. Epub 2020/05/28. https://doi.org/10.1186/s12981-020-00281-4 PMID: 32456686